CPT code 87637 represents the technical component of a multiplex molecular diagnostic assay that detects and differentiates SARS–CoV–2, influenza A, influenza B, and respiratory syncytial virus (RSV). This code is nationally relevant because multiplex respiratory virus testing plays a central role in public health surveillance, clinical management of respiratory illness, and laboratory workflows, especially during respiratory virus seasons and pandemics. Reimbursement and coverage policies for multiplex testing affect laboratory operations and patient access nationwide.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for multiplex respiratory viral testing, expected sites of service, and what aspects of reimbursement and policy are typically relevant for CPT code 87637. The publication summarizes common billing considerations, benchmark topics, and policy updates that affect laboratory billing for multiplex nucleic acid amplification tests. Where input data is not provided, the text notes that specific items are "Data not available in the input."